General Information of Synthetic Binding Protein (SBP) (ID: SBP000147)
SBP Name
BiTE AMG-562
Synonyms
AMG562
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Phase I
Protein Scaffold Information of This SBP
Scaffold ID PS018
Scaffold Info
[1] , [2]
Scaffold Name BiTE
Scaffold Class Antibody fragment
Fold Type Beta-Sheets + Loops
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
T-cell surface glycoprotein CD3
BTS Info
Binder B-cell non-hodgkin lymphoma [ICD-11: 2B33.5]; Follicular lymphoma [ICD-11: 2A80]; Mantle cell lymphoma [ICD-11: 2A85.5] N.A. Amgen [1] , [2]
B-lymphocyte antigen CD19
BTS Info
Modulator B-cell non-hodgkin lymphoma [ICD-11: 2B33.5]; Follicular lymphoma [ICD-11: 2A80]; Mantle cell lymphoma [ICD-11: 2A85.5] N.A. Amgen [1] , [2]
Clinical Trial Information of This SBP
NCT03571828 Click to show the Detail
Indication Relapsed or Refractory Diffuse Large B-cell Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma
Phase Phase I
Title A Phase I, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of?AMG 562?in Subjects With Relapsed / Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Status Active, not recruiting
Sponsor Amgen
References
1 Amgen. Product Development Pipeline. 2021.
2 The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020 Jul 15;126(14):3192-3201.